Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROP-2 ADC + Toripalimab for Resectable Locally Advanced Oral Squamous Cell Carcinoma
NCT07778368Phase 2Not yet recruiting
- Sponsor
- Shanghai East Hospital
- Start
- Sep 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab govitecan, sacituzumab tirumotecan, toripalimab in oral squamous cell carcinoma (OSCC), sponsored by Shanghai East Hospital. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
sacituzumab govitecansacituzumab tirumotecantoripalimab
03
Conditions
oral squamous cell carcinoma (OSCC)
Beyond the preview
Go deeper on NCT07778368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07778368.